Dados B3 › BIOM3 × HAPV3 · Português
Each row uses the most recent year in which BOTH companies have the figure, and says which year that is. A cell with ! carries a caveat — hover to read it. We do not name a winner: that would be a recommendation, and this site does not give any.
| indicator | BIOM3 | HAPV3 | year |
|---|---|---|---|
| ROE | -2.3% | -0.3% | 2025 |
| ROIC | -1.1%! | 1.8%! | 2025 |
| ROA | -1.4% | -0.2% | 2025 |
| Gross margin | 31.6% | 11.8% | 2025 |
| EBIT margin | -1.9% | 4.6% | 2025 |
| Net margin | -2.5% | -0.5% | 2025 |
| Net debt/EBITDA | 16.05x | 1.66x | 2025 |
| Current ratio | 2.23x | 1.90x | 2025 |
| Revenue growth (1y) | 88.4% | 9.2% | 2025 |
| Revenue growth (5y CAGR) | 35.6% | 29.8% | 2025 |
| Piotroski F-Score | 4/9 | 6/9 | 2025 |
Priced at the first session on or after the day each filing became public — never the period close.
| indicator | BIOM3 | HAPV3 | year |
|---|---|---|---|
| P/E | -146.52x | -27.50x | 2025 |
| P/B | 3.13x | 0.08x | 2025 |
| EV/EBITDA | 310.46x | 2.95x | 2025 |
| FCF yield | -14.1% | 26.2% | 2025 |
Numbers on this page are live. Data version 2026-09-01-supressao-declarada · page generated 2026-09-08 14:49 UTC. If this does not match /saude, you are reading a cached copy.
Home · Methodology · Transparency · Audit it